{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:50:40Z","timestamp":1778943040440,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K08809"],"award-info":[{"award-number":["JP19K08809"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K08772"],"award-info":[{"award-number":["JP21K08772"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004713","name":"Hospital Universiti Sains Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jphs.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T02:32:30Z","timestamp":1651890750000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia"],"prefix":"10.1016","volume":"149","author":[{"given":"Masamitsu","family":"Takaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3735-3718","authenticated-orcid":false,"given":"Takayuki","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2022.04.009_bib1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jphs.2022.04.009_bib2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2022.04.009_bib3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jphs.2022.04.009_bib4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2022.04.009_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2022.04.009_bib6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2022.04.009_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jphs.2022.04.009_bib8","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41375-018-0247-1","article-title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","volume":"32","author":"Aghel","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jphs.2022.04.009_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jphs.2022.04.009_bib10","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","article-title":"Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database","volume":"97","author":"Fujioka","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jphs.2022.04.009_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.jphs.2022.04.009_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cancers12051242","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of CML: a meta-analysis","volume":"12","author":"Haguet","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jphs.2022.04.009_bib13","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jphs.2022.04.009_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","article-title":"The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p","volume":"58","author":"Sukegawa","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.jphs.2022.04.009_bib15","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","article-title":"Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway","volume":"9","author":"Ai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jphs.2022.04.009_bib16","doi-asserted-by":"crossref","first-page":"e12625","DOI":"10.1111\/micc.12625","article-title":"BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature","volume":"27","author":"Durand","year":"2020","journal-title":"Microcirculation"},{"key":"10.1016\/j.jphs.2022.04.009_bib17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2022.04.009_bib18","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jphs.2022.04.009_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jphs.2022.04.009_bib20","first-page":"1878964","article-title":"Characterization of atherosclerosis formation in a murine model of type IIa human familial hypercholesterolemia","author":"Miyajima","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jphs.2022.04.009_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.jphs.2022.04.009_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147005","article-title":"Dasatinib reduces lung inflammation and fibrosis in acute experimental silicosis","volume":"11","author":"Cruz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2022.04.009_bib23","doi-asserted-by":"crossref","first-page":"104357","DOI":"10.1016\/j.phrs.2019.104357","article-title":"Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism","volume":"147","author":"Zeng","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jphs.2022.04.009_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2015.11.027","article-title":"Protein sorting gone wrong--VPS10P domain receptors in cardiovascular and metabolic diseases","volume":"245","author":"Schmidt","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jphs.2022.04.009_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/CIRCRESAHA.116.305811","article-title":"Macrophage sortilin promotes ldl uptake, foam cell formation, and atherosclerosis","volume":"116","author":"Patel","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2022.04.009_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.atherosclerosis.2012.10.026","article-title":"Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemia","volume":"225","author":"Tveten","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jphs.2022.04.009_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2009.06.034","article-title":"Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease","volume":"208","author":"Linsel-Nitschke","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jphs.2022.04.009_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cmet.2010.08.006","article-title":"Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export","volume":"8","author":"Kjolby","year":"2010","journal-title":"Cell Metabol"},{"key":"10.1016\/j.jphs.2022.04.009_bib29","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1172\/JCI76002","article-title":"Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis","volume":"124","author":"Mortensen","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2022.04.009_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1194\/jlr.M089789","article-title":"Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice","volume":"60","author":"Chen","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jphs.2022.04.009_bib31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nature09266","article-title":"From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus","volume":"466","author":"Musunuru","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jphs.2022.04.009_bib32","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1172\/JCI24061","article-title":"Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice","volume":"115","author":"Moore","year":"2005","journal-title":"J\u00a0Clin Invest"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:02:55Z","timestamp":1761163375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1347861322000366"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.04.009","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}